A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD–mutant acute myeloid leukemia

FMS-like tyrosine kinase 3 (FLT3) tyrosine kinase inhibitors (TKIs) have activity in acute myeloid leukemia (AML) patients with FLT3 internal tandem duplication (ITD) mutations, but efficacy is limited by resistance-conferring kinase domain mutations. This phase 1/2 study evaluated the safety, toler...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood Adv
Autori principali: Smith, Catherine C., Levis, Mark J., Frankfurt, Olga, Pagel, John M., Roboz, Gail J., Stone, Richard M., Wang, Eunice S., Severson, Paul L., West, Brian L., Le, Mai H., Kayser, Sabine, Lam, Bao, Hsu, Henry H., Zhang, Chao, Bollag, Gideon, Perl, Alexander E.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2020
Soggetti:
Myeloid Neoplasia
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7189289/
https://ncbi.nlm.nih.gov/pubmed/32330242
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020001449
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi